Varian Medical Systems, Inc designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through two segments, Oncology Systems and Proton Solutions. The Oncology Systems segment offers hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, and brachytherapy, as well as related quality assurance equipment.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Phone650-493-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.92 billion
Profitability
Miscellaneous
Employees7,174
Next Earnings Date10/23/2019 (Confirmed)
OptionableOptionable
Varian Medical Systems (NYSE:VAR) Frequently Asked Questions
What is Varian Medical Systems' stock symbol?
Varian Medical Systems trades on the New York Stock Exchange (NYSE) under the ticker symbol "VAR."
How were Varian Medical Systems' earnings last quarter?
Varian Medical Systems, Inc. (NYSE:VAR) released its quarterly earnings results on Wednesday, July, 24th. The medical equipment provider reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.18. The medical equipment provider had revenue of $825.80 million for the quarter, compared to analysts' expectations of $762.29 million. Varian Medical Systems had a net margin of 10.75% and a return on equity of 24.91%. The firm's revenue for the quarter was up 16.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.04 earnings per share. View Varian Medical Systems' Earnings History.
When is Varian Medical Systems' next earnings date?
How can I listen to Varian Medical Systems' earnings call?
Varian Medical Systems will be holding an earnings conference call on Wednesday, October 23rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Varian Medical Systems issued on next quarter's earnings?
Varian Medical Systems updated its FY19 earnings guidance on Wednesday, July, 24th. The company provided EPS guidance of $4.58-4.63 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.67. The company issued revenue guidance of $3.18-3.21 billion, compared to the consensus revenue estimate of $3.15 billion.
What price target have analysts set for VAR?
9 brokers have issued 12 month price targets for Varian Medical Systems' stock. Their forecasts range from $105.00 to $165.00. On average, they expect Varian Medical Systems' stock price to reach $142.00 in the next year. This suggests a possible upside of 28.1% from the stock's current price. View Analyst Price Targets for Varian Medical Systems.
What is the consensus analysts' recommendation for Varian Medical Systems?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Varian Medical Systems in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Varian Medical Systems.
What are Wall Street analysts saying about Varian Medical Systems stock?
Here are some recent quotes from research analysts about Varian Medical Systems stock:
- 1. Barrington Research analysts commented, "We strongly suspect that radiation that is delivered via the Ethos system will receive very high marks from both clinicians and patients alike. Ethos currently has its CE Mark while a 510(k) regulatory clearance in the U.S. is still pending." (9/23/2019)
- 2. According to Zacks Investment Research, "Varian ended the fiscal third quarter on a solid note, with strength in the core Oncology arm. Growth in EMEA and China also buoys optimism. In fact, management foresees tremendous opportunities in China for its radiation therapy products. Also, Varian’s proton therapy products pipeline is healthy. Management is optimistic about the recently-closed acquisitions of CyberHeart, Cancer Treatment Services International, Endocare and Alicon. A raised revenue guidance paints a bright picture. While expansion in the operating margin is an added positive, contraction in gross margin raises concern. Additionally, the U.S.-China tariffs have been affecting Varian’s top line for a couple of quarters now. Varian also saw softness in its Proton as well as U.S. and APAC businesses in the quarter. A narrowed EPS view adds to the woes." (7/27/2019)
- 3. BTIG Research analysts commented, "For its fiscal first quarter, Varian again outperformed on two key metrics: revenue and Oncology gross orders. Revenue of $741.0M topped consensus by ~$20M while Oncology gross orders of $716.5M was ~$60M above estimates. We like that Oncology gross order growth of +17% y/y CC was the highest in a decade and that the strength came from all regions. Still, with VAR shares trading near all-time historical highs, investors were likely seeking perfection. VAR may trade up Thursday, but with gross margins and operating margins coming in below consensus models, we think the positive stock reaction may be just a few dollars." (1/24/2019)
Has Varian Medical Systems been receiving favorable news coverage?
Press coverage about VAR stock has been trending negative this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Varian Medical Systems earned a news impact score of -2.6 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Varian Medical Systems.
Who are some of Varian Medical Systems' key competitors?
Some companies that are related to Varian Medical Systems include SONOVA HLDG AG/ADR (SONVY), Masimo (MASI), GETINGE AB/ADR (GNGBY), LivaNova (LIVN), CONMED (CNMD), Natus Medical (BABY), Natus Medical (NTUS), InMode (INMD), AxoGen (AXGN), TransMedics Group (TMDX), Cutera (CUTR), Zynex (ZYXI), BioLife Solutions (BLFS), Semler Scientific (SMLR) and Viewray (VRAY).
What other stocks do shareholders of Varian Medical Systems own?
Who are Varian Medical Systems' key executives?
Varian Medical Systems' management team includes the folowing people:
- Mr. Dow R. Wilson, Pres, CEO & Director (Age 60)
- Mr. Gary E. Bischoping Jr., Sr. VP of Fin. & CFO (Age 51)
- Mr. John W. Kuo, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
- Ms. Kolleen T. Kennedy, Chief Growth Officer & Pres of Proton Solutions (Age 60)
- Mr. Kevin O'Reilly, Sr. VP of Global Operations
Who are Varian Medical Systems' major shareholders?
Varian Medical Systems' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.04%), Pacer Advisors Inc. (0.01%), Crossmark Global Holdings Inc. (0.01%), Douglass Winthrop Advisors LLC (0.01%), Orrstown Financial Services Inc. (0.01%) and Rockland Trust Co. (0.01%). Company insiders that own Varian Medical Systems stock include Christopher A Toth, David J Illingworth, Dow R Wilson, Gary E Bischoping Jr, John W Kuo, Kolleen T Kennedy, Magnus Momsen, Mark R Laret, R Andrew Eckert, Susan L Bostrom and Timothy E Guertin. View Institutional Ownership Trends for Varian Medical Systems.
Which institutional investors are selling Varian Medical Systems stock?
VAR stock was sold by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC and Crossmark Global Holdings Inc.. Company insiders that have sold Varian Medical Systems company stock in the last year include Christopher A Toth, Dow R Wilson, Gary E Bischoping Jr, John W Kuo, Kolleen T Kennedy, Magnus Momsen, R Andrew Eckert and Timothy E Guertin. View Insider Buying and Selling for Varian Medical Systems.
Which institutional investors are buying Varian Medical Systems stock?
VAR stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Douglass Winthrop Advisors LLC, Pacer Advisors Inc., MA Private Wealth, Orrstown Financial Services Inc. and Rockland Trust Co.. View Insider Buying and Selling for Varian Medical Systems.
How do I buy shares of Varian Medical Systems?
Shares of VAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Varian Medical Systems' stock price today?
One share of VAR stock can currently be purchased for approximately $110.82.
How big of a company is Varian Medical Systems?
Varian Medical Systems has a market capitalization of $10.09 billion and generates $2.92 billion in revenue each year. The medical equipment provider earns $149.90 million in net income (profit) each year or $4.42 on an earnings per share basis. Varian Medical Systems employs 7,174 workers across the globe.View Additional Information About Varian Medical Systems.
What is Varian Medical Systems' official website?
How can I contact Varian Medical Systems?
Varian Medical Systems' mailing address is 3100 Hansen Way, Palo Alto CA, 94304. The medical equipment provider can be reached via phone at 650-493-4000 or via email at [email protected]
MarketBeat Community Rating for Varian Medical Systems (NYSE VAR)
MarketBeat's community ratings are surveys of what our community members think about Varian Medical Systems and other stocks. Vote "Outperform" if you believe VAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VAR will underperform the S&P 500 over the long term. You may vote once every thirty days.
